DLX105-DMP
/ DelArrivo
- LARVOL DELTA
Home
Next
Prev
1 to 4
Of
4
Go to page
1
May 03, 2023
A Study of DLX105-DMP in Subjects With Plaque Psoriasis
(clinicaltrials.gov)
- P1 | N=10 | Completed | Sponsor: DelArrivo, Inc. | Recruiting ➔ Completed | Phase classification: P1/2 ➔ P1 | N=18 ➔ 10
Enrollment change • Phase classification • Trial completion • Dermatology • Immunology • Psoriasis
November 23, 2021
A Study of DLX105-DMP in Subjects With Plaque Psoriasis
(clinicaltrials.gov)
- P1/2; N=18; Recruiting; Sponsor: DelArrivo, Inc.; Not yet recruiting ➔ Recruiting; N=12 ➔ 18; Trial completion date: Nov 2021 ➔ Mar 2022; Trial primary completion date: Nov 2021 ➔ Mar 2022
Clinical • Enrollment change • Enrollment open • Trial completion date • Trial primary completion date • Dermatology • Immunology • Psoriasis
August 18, 2021
A Study of DLX105-DMP in Subjects With Plaque Psoriasis
(clinicaltrials.gov)
- P1/2; N=12; Not yet recruiting; Sponsor: DelArrivo, Inc.; Trial completion date: Jul 2021 ➔ Nov 2021; Trial primary completion date: Jul 2021 ➔ Nov 2021
Clinical • Trial completion date • Trial primary completion date • Dermatology • Immunology • Psoriasis
February 24, 2021
A Study of DLX105-DMP in Subjects With Plaque Psoriasis
(clinicaltrials.gov)
- P1/2; N=12; Not yet recruiting; Sponsor: DelArrivo, Inc.; N=20 ➔ 12; Trial completion date: Sep 2020 ➔ Jul 2021; Trial primary completion date: Sep 2020 ➔ Jul 2021
Clinical • Enrollment change • Trial completion date • Trial primary completion date • Dermatology • Immunology • Psoriasis
1 to 4
Of
4
Go to page
1